New drug JNJ-89402638 enters human trials for Tough-to-Treat GI cancers
NCT ID NCT06663319
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined with standard chemotherapy and/or bevacizumab. About 260 participants will be enrolled to monitor side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-89402638 (an experimental drug) given alone or with bevacizumab and/or chemotherapy (FOLFOX or FOLFIRI)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced colorectal or gastric cancer who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 study focused on safety and dosing, not on proving the drug works. Many experimental cancer drugs fail in early testing, and side effects like cytokine release syndrome are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE/METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46256, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Hosp Univ Fund Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hosp Univ Hm Sanchinarro
RECRUITINGMadrid, 28050, Spain
-
Hosp Univ Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hosp. Univ. 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Severance Hospital Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Start Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Swedish Cancer Institute
RECRUITINGSeattle, Washington, 98104, United States
-
University of Colorado Denver Anschultz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States